1 of 1
Story summary
- The Democratic Republic of Congo has launched the EBO-PEP trial to treat high-risk Ebola contacts, focusing on children.
- Since mid-May, the outbreak has killed over 3,000 people, with children under five experiencing over 60% mortality.
- The protocol now allows children weighing over 20 kg to receive experimental antiviral obeldesivir, while those under 20 kg remain excluded.
- Remdesivir is an alternative for under-20 kg children, but its 10-day IV infusion is difficult during outbreaks.
